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Effects of anti-TGF- type II receptor antibody on experimen- Renal fibrosis may occur in etiologically diverse renal
tal glomerulonephritis diseases, including immunologically mediated glomeru-
Background. Renal fibrosis, characterized by the accumula- lonephritis, hemodynamic disorders, and metabolic andtion of extracellular matrix (ECM), is a common histopatholog-
hereditary diseases. Excessive deposition of extracellularical feature of progressive renal disease of diverse etiology.
matrix (ECM) is the characteristic feature of organ fi-Interaction between transforming growth factor- (TGF-) and
TGF- type II receptor (TGF-IIR) may play an important role brosis. Lots of mediators are involved in the develop-
in the ongoing fibrotic process. TGF-IIR and TGF- have been ment of scarring and fibrotic conditions. Transforming
reported to be up-regulated in human glomerulopathies. In order
growth factor- (TGF-) is known to play an importantto block the TGF- system, many studies have inhibited TGF-
role in this process [1]. Generally, TGF- induces theitself, but not its receptors. Our study explored the effects of
fully human monoclonal antibody against TGF-IIR (hTGF- deposition of ECM via stimulation of ECM production
IIRAb) on experimental proliferative glomerulonephritis. [2], down-regulation of ECM-degrading proteases and
Methods. hTGF-IIRAb was generated from Xenomice. The up-regulation of protease inhibitors [3]. By these mecha-expression of TGF-IIR was studied by immunohistochemistry
nisms, TGF- is thought to be involved in the progressionin normal and anti-Thy-1 nephritis rats. hTGF-IIRAb or con-
of renal fibrosis. Therefore, inhibition of TGF- is con-trol Ab was injected intraperitoneally at day 0 and day 4 of
anti-Thy-1 nephritis, and rats were sacrificed at day 7. Effects sidered to be one of the crucial therapeutic strategies to
of hTGF-IIRAb were assessed by histological and immuno- prevent renal fibrosis. Inhibition of TGF- by neutraliz-
pathological measurements.
ing antibody [4], anti-sense oligonucleotide [5], decorinResults. The specificity of hTGF-IIRAb was confirmed by
[6, 7], and TGF- receptor–IgG Fc chimera [8] sup-ELISA and Western blot analysis. By immunostaining, TGF-
IIR expression was up-regulated in the proliferative lesions pressed the accumulation of ECM in experimental prolif-
of anti-Thy-1 nephritis at day 7. In the hTGF-IIRAb-treated erative glomerulonephritis induced by anti-Thy-1 anti-
group, the extent of mesangial expansion was less than that in body. However, all of these reports showed the effectsthe control group. By immunohistology, -smooth muscle ac-
of inhibition of TGF- itself, but not TGF- receptors.tin, fibronectin-EDA, and type I collagen were significantly re-
Transforming growth factor- regulates cellular pro-duced in the hTGF-IIRAb-treated group.
Conclusions. Anti-TGF-IIR antibody ameliorated ECM cesses by binding to three high-affinity cell-surface recep-
accumulation in anti-Thy-1 nephritis. Our data suggest that tors: types I, II, and III [9]. In the extracellular space,
TGF-IIR may be one of the therapeutic targets, and that fully
TGF- binds either to the type III receptor, which pre-human monoclonal antibody against TGF-IIR may have a
sents it to the type II receptor (TGF-IIR), or directlynew therapeutic potential for renal fibrosis.
to TGF-IIR on the cell membrane. Then the TGF--
TGF-IIR complex binds to the type I receptor, and
finally, phosphorylation of the type I receptor occurs
[10]. Phosphorylation activates several signaling path-
ways, including the Smad pathway, and regulates multi-Key words: human monoclonal antibody, fibronectin-EDA, renal fi-
brosis, extracellular matrix, proliferative glomerular nephritis, scarring. ple TGF- functions [11]. In this respect, TGF-IIR is
important for the TGF- signaling pathway. Therefore,
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monoclonal antibodies in mice was established with TGF-IIR (sTGF-IIR) emulsified with an equal vol-
ume of Freund’s complete adjuvant (FCA; ICN/Cappel,therapeutic potential [12, 13]. Using this technique, we
developed a fully human monoclonal antibody against Aurora, OH, USA). These mice were repeatedly immu-
nized every week for one month with recombinant sTGF-TGF-IIR. Our study explored the effects of fully human
anti-human TGF-IIR antibody on the anti-Thy-1 ne- IIR in Freund’s incomplete adjuvant (ICN/Cappel). The
final booster injection was performed two days prior tophritis. To our knowledge this is the first report of a direct
inhibition of TGF- receptor function in experimental fusion. Popliteal lymph node cells were fused with mouse
myeloma cell lines, P3/X63-Ag8.653, using PEG4000 (Lifeglomerulonephritis.
Technologies, Grand Island, NY, USA). Supernatants
of the growing hybridomas were tested by direct enzyme-
METHODS
linked immunosorbent assay (ELISA) against human
Cells sTGF-IIR.
A hybridoma, JMAb-45 (IgG4), was cloned and con-Mouse myeloma cells, P3/X63-Ag8.653 (CRL-1580;
American Type Culture Collection, Manassas, VA, USA), firmed to recognize human sTGF-IIR. Cross-reactivity
of JMAb-45 against rat TGF-IIR was checked by thewere cultured in Dulbecco’s modified Eagle’s medium
(DMEM; Nikken Biomedical, Kyoto, Japan) containing immunohistochemical study on rat kidney cell lines,
NRK (CRL-6509; ATCC) and on normal rat kidney10% fetal bovine serum (FBS; Moregate, Australia). Hu-
man embryonal kidney cells, HEK293 (CRL-1573, ATCC), tissues.
Control antibody, JMAb-77 (IgG4), was generated bywere cultured in DMEM medium containing 10% FBS.
Mouse/mouse hybridomas were cultured in ASF104 me- immunization with keyhole limpet hemocyanin (KLH;
Pierce, Rockford, IL, USA).dium (Ajinomoto, Tokyo, Japan) supplemented with
10% FBS. All cells were cultured at 37C with 5% CO2.
Direct ELISA procedure
Animals Enzyme-linked immunosorbent assays were performed
at room temperature. Each well of the 96-well plate (NalgeXenomice, which generate high-affinity fully human
antibodies to multiple antigens, were maintained in the Nunc International, Rochester, NY, USA) was incubated
for one hour with 0.2 g sTGF-IIR (241-R2/CF, R&D)Pharmaceutical Frontier Research Laboratories (Cen-
tral Pharmaceutical Research Institute, Japan Tobacco in 50L phosphate-buffered saline (PBS). Each well was
then blocked for two hours with Block Ace (DainipponInc.) [12, 13]. Seven-week-old female Wistar rats were
purchased from Chubu Kagaku Shizai Co. Ltd. (Nagoya, Pharmaceutical, Osaka, Japan). After washing with PBS
containing 0.1% Tween 20 (Bio-Rad Laboratories, Her-Japan) and were allowed free access to food and water.
The experiments were performed according to the Ani- cules, CA, USA; PBS/T), each well was incubated for
one hour with 0.0003 to 10 g/mL JMAb-45 in 50 Lmal Experimentation Guide of Nagoya University School
of Medicine (Nagoya, Japan). PBS/T. Wells were subsequently washed three times with
PBS/T and incubated for one hour with 50 L horserad-
Production and purification of soluble TGF-IIR ish peroxidase labeled anti-human IgG antibody (Amer-
sham Pharmacia Biotech, Buckinghamshire, UK) in PBS/THEK293 cells were transfected with the plasmid con-
taining the cDNA for the extracellular domain (amino containing 0.5% bovine serum albumin (BSA fraction
V; Nacalai Tesque, Kyoto, Japan). After washing fouracids 1 to 159) of human TGF-IIR. The recombinant
soluble TGF-IIR was purified by antibody affinity chro- times with PBS/T, each well was incubated with 100 L
tetramethyl bendidine (Bio-Rad Laboratories). The reac-matography using anti-human TGF-IIR polyclonal an-
tibody (AF-241-NA; R&D Systems, Minneapolis, MN, tion was terminated by 25 L 0.5 N sulfuric acid, and the
absorbance at 450 nm was read on a microplate reader,USA), and then its purity was examined by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) M-Tmax (Molecular Devices, Sunnyvale, CA, USA).
and silver staining. The purified human TGF-IIR was
Western blot analysisused for immunization.
Soluble TGF-IIR (R&D) protein was diluted in equal
Generation and characterization of anti-human amounts of 2Tris-SDS seprasol buffer (Dai-ichi Chemi-
TGF-IIR monoclonal antibodies cal, Tokyo, Japan) under an unreduced condition and
boiled for five minutes. The protein samples were runXenomice are characterized by gene targeted-inacti-
vated mouse heavy and  chain loci and transgenic for through a 10%/20% gradient acrylamide gel (Dai-ichi
Chemical). Different concentrations of sTGF-IIR sam-human heavy and  chain loci. Thus, these mice are
deficient in murine antibody production, but produce ples and molecular-weight standards (7711BTS; New En-
gland BioLabs, Beverly, MA, USA) were subjected tohuman antibodies [12, 13]. Xenomice were immunized
once by subcutaneous injection of recombinant soluble electrophoresis for one hour at 40 mA on the vertical
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Table 1. Experimental protocolgel apparatus (Bio-Rad Laboratories). The separated
proteins on the SDS gel were transferred electrophoreti- Number of rats
Reagent
cally to an Immobilon-P polyvinylidine difluoride (PVDF) Group injection Treatment Day 1 Day 3 Day 7
transfer membrane (Millipore, Tokyo, Japan).
I mAb 1-22-3 IV JMAb-45 IP 6 6 10
After transfer, the membrane was washed in PBS/T II mAb 1-22-3 IV JMAb-45 IP 6 6 10
III Saline IV None 5 5 5and then incubated with Block Ace at room temperature
Abbreviations are: IV, intravenous injection; IP, intraperitoneal injection.for two hours on a shaker to block nonspecific antibody
binding sites. The membrane was washed in Tris-buf-
fered saline (TBS; Takara, Kyoto, Japan) containing
0.1% Tween 20 (TTBS) and incubated with JMAb-45, Table 1. Tissues for light microscopy were fixed with
JMAb-77 or polyclonal goat anti-human TGF-IIR anti- methacarn overnight, dehydrated through graded etha-
body (R&D) for 1.5 hours at room temperature. After nol series and embedded in paraffin. Histologic sections
washing with TTBS, the membrane was incubated with of kidneys were stained with periodic acid-Schiff (PAS)
anti-human Ig biotinylated sheep whole antibody (Amer- and hematoxylin and eosin (HE). A part of the tissues
sham Pharmacia Biotech) or anti-goat Ig biotinylated was snap frozen in liquid nitrogen for immunostaining.
donkey whole antibody (Amersham Pharmacia Biotech)
Immunostainingdiluted with TTBS for one hour at room temperature.
Two-micrometer-thick frozen sections were cut by aAfter washing with TTBS, immobilized antibodies were
cryostat, air dried, and fixed in acetone at room tempera-detected by luminol reagents (ECL Western blotting
ture for 10 minutes. For analysis of glomerular macrophagereagents; Amersham Pharmacia Biotech); subsequently,
infiltration, sections were incubated with mAb ED1 (anti-the membrane was exposed to ECL hyper-film (Amer-
rat-macrophage/monocyte, mouse IgG1; BMA), followedsham Pharmacia Biotech) for 30 seconds in the dark to
by FITC-labeled goat anti-mouse IgG antibody (Cappelvisualize the specific protein bands.
Laboratory, West Chester, PA, USA) as the second re-
Urinary protein excretion agent.
For immunohistological analysis, endogenous peroxi-Rats were housed in metabolic cages overnight from
dase activity was inhibited with 0.1% NaN3 and 0.3%day 0 to day 1, from day 2 to day 3, and from day 6 to
hydrogen peroxide in PBS and nonspecific protein-bindingday 7. Urinary protein was measured by a pyrogallol red
sites were blocked with normal goat serum. The sectionsmethod [14].
were incubated with mAb 1A4 [anti--smooth muscle
actin (-SMA) antibody, mouse IgG2a; Dako, Glostrup,Serum creatinine level
Denmark], IST-9 (anti-cellular fibronectin EDA domain,Serum of each rat was collected at day 3 and at day 7.
mouse IgG1; Harlan Sera-lab, Sussex, UK), or rabbitSerum creatinine was measured using the CRE-EN
polyclonal anti-collagen I (Chemicon International, Te-Kainos kit (Kainos, Tokyo, Japan).
mecula, CA, USA), followed by a conjugate of poly-
clonal goat anti-mouse IgG antibodies or goat anti-rabbitExperimental protocol
IgG antibodies, horseradish peroxidase and dextran back-Experimental proliferative glomerulonephritis was in-
bones (EnVision System; Dako) as the second reagent.
duced in female Wistar rats by intravenous injection of To detect the localization of TGF-IIR in rat and mouse
the monoclonal antibody (mAb) 1-22-3 (mouse IgG3) kidney, endogenous biotin present in the renal tissues
[15]. Thirty-nine rats were divided into three groups. was blocked with avidin/biotin blocking kit in two succes-
Rats of group I (N  22) and II (N  22) were injected sive steps (Vector, Burlingame, CA, USA). Then tissues
intravenously with 500 g of mAb 1-22-3 in 1.0 mL were incubated with JMAb-45. Immobilized human anti-
saline as described previously [15]. Group I rats were bodies were detected by biotin-avidin-immunoperoxi-
intraperitoneally injected with anti-TGF-IIR antibody dase technique using Vectastain ABC kit human IgG
(JMAb-45, 5 mg/kg) at one hour and four days after mAb (Vector). Finally, the enzyme activity of horseradish per-
1-22-3 injection. Rats of group II were intraperitoneally oxidase was detected using 3-amino-9-ethyl-carbazole
injected with anti-KLH antibody (JMAb-77, 5 mg/kg) (Dako) or 3,3-diaminobenzidine tetrahydrochloride liq-
instead of anti-TGF-IIR antibody at the same time uid system (Dako). Negative controls were performed by
points. An additional 15 rats were injected intravenously replacement of first step antibodies by isotype-matched
with 1.0 mL of saline at day 0 and studied as normal mAb or species-matched antibody.
controls (group III). At day 1, six rats of group I, six
Morphometric analysis of histologygroup II, and five group III rats were sacrificed. At day
and immunohistology3, six rats of group I, six group II, and five group III
rats were sacrificed. At day 7, the remaining rats were For each kidney and for each type of staining, cross
sections of 20 different glomeruli and twenty differentsacrificed. The experimental protocol is summarized in
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tubulointerstitial areas of 0.1 mm2 were examined as
described previously [16]. The total number of nuclei in
each glomerulus was counted using tissues stained by
PAS. The average number of cells/glomerulus was calcu-
lated and used as a representative number. The number
of macrophages was counted, and the average numbers
per glomerulus were calculated. In each glomerulus, ra-
tio of area positively stained for -SMA, fibronectin-
EDA, or type I collagen to total glomerular area was
measured by computer-aided planimetry using Mac Scope
(Mitani, Fukui, Japan) and expressed as a percentage.
Similarly, the ratio of positively stained area in 0.1 mm2
of tubulointerstitial area was measured [16].
Statistical analysis
All values are provided as mean 	 SD. Statistical
analysis was performed by one-way analysis of variance
(ANOVA). When significant difference was present, sta-
tistical analysis was further performed using the Scheffe
F test between two groups. Significant difference was set
when the P value was less than 0.05 (5%).
RESULTS
Characterization of fully human anti-TGF-IIR
monoclonal antibody
ELISA. The direct ELISA for sTGF-IIR showed that
anti-TGF-IIR antibody, JMAb-45, detected sTGF-IIR
in a dose-dependent manner from 0.01 to 10 g/mL
of JMAb-45 concentration (Fig. 1A). Control antibody
(JMAb-77) did not react with sTGF-IIR (Fig. 1A)
Western blot analysis. Western blotting showed that
JMAb-45 specifically detected proteins of 20 to 30 kD.
The molecular size of the band reacted with JMAb-45
was similar to that identified by other polyclonal anti-
TGF-IIR antibody (R&D; Fig. 1B).
Urinary protein excretion
At day 1 and day 3, the urinary protein of groups I
and II was increased when compared with the normal
group; however, those were not significantly different
Fig. 1. Direct enzyme-linked immunosorbent assay (ELISA) andbetween groups I and II (day 1, group I, 11.7 	 4.6 mg/
Western blot analysis. (A) Direct ELISA shows specific detection ofday; group II, 11.3 	 6.3 mg/day; group III, 2.9 	 0.9 sTGF-IIR by JMAb-45 () in a dose-dependent manner, but not by
mg/day; day 3, group I, 38.3 	 22.7 mg/day; group II, JMAb-77 (). (B) Western blot analysis shows 20-30 kD sTGF-IIR
broad band detected by JMAb-45 and anti-TGF-IIR (R&D), but not27.6 	 19.9 mg/day; group III, 3.0	0.9 mg/day; Fig. 2A).
by JMAb-77. Lane 1, sTGF-IIR 0.05 g/lane, JMAb-77 2 g/mL; laneAt day 7, the urinary protein of group I was significantly 2, sTGF-IIR 0.5 g/lane, JMAb-45 2 g/mL; lane 3, sTGF-IIR 0.05
less than that of group II (53.2 	 22.9 mg/day vs. 90.7 	 g/lane, JMAb-45 2 g/lane; lane 4, sTGF-IIR 0.05 g/lane, anti-
TGF-IIR polyclonal antibody (R&D) 0.05g/mL, as a positive control.25.8 mg/day, P 
 0.005). The urinary protein excretion
of group III was significantly less than that of groups I
and II (3.0 	 1.0 mg/day, P 
 0.005 vs. group I, P 

0.0001 vs. group II; Fig. 2A). group II, 0.45 	 0.03 mg/dL; group III, 0.45 	 0.02 mg/
dL). At day 7, the serum creatinine level of group II was
Serum creatinine level significantly elevated when compared with that of groups
At day 3, the serum creatinine level was not different I or III (group I, 0.65 	 0.13 mg/dL; group II, 0.78 	
0.09 mg/dL; group III, 0.60 	 0.02 mg/dL, P 
 0.005among the three groups (group I, 0.44 	 0.02 mg/dL;
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expression of TGF-IIR in normal murine kidney. The
expression pattern was similar to that of normal rat kid-
ney (data not shown).
Light microscopic findings
At day 1 and day 3, almost all glomeruli in group I
and group II showed mesangiolysis (Fig. 4). These find-
ings were not different between group I and group II.
At day 7, mesangial area of group II was expanded in
almost all glomeruli (Fig. 3D). In several glomeruli, mi-
croaneurysm formation, the advanced form of mesangio-
lysis, was still observed. These pathological findings were
comparable to the findings reported previously in anti-
Thy-1 nephritis at day 7 [15]. On the other hand, in group
I the extent of mesangial expansion was less than that
of group II (Fig. 3C).
-SMA expression and ECM deposition in glomerulus
By immunohistochemistry, -SMA expression was
confined to blood vessels, but was not detected in the
glomeruli of group III rat (Fig. 3H). In group II rats, the
-SMA-positive area was significantly increased (Fig.
3G). Expression of -SMA in group I (Fig. 3F) was
significantly decreased when compared with group II
(Fig. 3G). Using a computer-aided analyzer, -SMA ex-
pression was quantitatively measured. -SMA expres-
sion in group I was significantly suppressed when com-
pared to that in group II. Rats of group III did not
express -SMA in glomeruli (Fig. 5A).
Fibronectin-EDA was not detected or weakly positive
in the glomerulus from group III rats (Fig. 3K). In group
II, fibronectin-EDA was markedly increased in mesan-Fig. 2. Urinary protein excretion and serum creatinine levels in ()
gial area and in periglomerular area (Fig. 3J). In contrast,group I, () group II, and () group III. (A) At days 1 and 3 the
urinary protein excretion was not different between groups I and II. the glomerular staining of fibronectin-EDA was dramati-
At day 7, urinary protein excretion was significantly increased in group cally decreased in rats of group I (Fig. 3I). The resultsII compared to group III. Urinary protein excretion was significantly
obtained from type I collagen staining showed similarreduced by injection of JMAb-45 (group I) compared with group II,
but was still larger than that of group III (*P 
 0.05 vs. group III; #P 
 results. Quantitative data from the computer-aided ana-
0.05 vs. group III; **P 
 0.05 vs. group III; ##P 
 0.05 vs. group III; lyzer are shown in Figure 5A.***P 
 0.005 vs. group II; P 
 0.005 vs. group III; ###P 
 0.0001 vs.
group III, respectively). (B) At day 3, serum creatinine level among
-SMA expression and ECM depositionthree groups was not significantly different. At day 7, serum creatinine
level of group II was significantly increased compared with group III in interstitium
(#P 
 0.05 vs. group III). Serum creatinine level was significantly sup-
In group III rats, the -SMA expression was confinedpressed by injection of JMAb-45 (group I, *P 
 0.05 vs. group II). The
difference between group I and group III was statistically not significant. to blood vessel walls. In groups I and II, -SMA was
faintly but significantly stained in a part of tubular epithe-
lial cells.
In group III, fibronectin-EDA was weakly positive ingroup II vs. groups I or III), while those were not signifi-
the tubulointerstitial area (Fig. 3N). In group II, expres-cantly different between groups I and III (Fig. 2B).
sion of fibronectin-EDA was increased especially in
TGF-IIR expression outer medulla (Fig. 3M). The expression in group I (Fig.
3L) was significantly less than that of group II. The ex-In normal rat kidney, TGF-IIR was expressed mainly
pression of type I collagen was similar with that of fibro-by glomerular epithelial cells and was faintly detected
nectin-EDA. Quantitative analysis showed that the dif-in the apical sites of tubular epithelial cells (Fig. 3A). In
ferences in the fibronectin-EDA and type I collagen-anti-Thy-1 nephritis, the expression of TGF-IIR was
positive area were statistically significant among theup-regulated in glomerulus at day 7, especially by prolif-
erated mesangial cells (Fig. 3B). We also examined the three groups (Fig. 5B).
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Fig. 4. Light microscopic findings at day 1 and day 3. Light microscopic findings at day 1 and day 3 are shown by PAS stain (400). Panel A
shows group I at day 1; B, group II at day 1; C, group I at day 3; D, group II at day 3. At day 1 and day 3, almost all glomeruli showed mesangiolysis
and cellular infiltration in both groups. These findings were not different between two groups.
Number of total glomerular cells and glomerular cells was significantly increased in groups I
glomerular macrophages and II compared with group III. The number of total
glomerular cells in group I was slightly decreased whenAt day 1 and day 3, the number of total glomerular
compared with group II (P 
 0.01; Fig. 6A).cells was significantly decreased in groups I and II com-
Glomerular macrophages were rarely detected inpared with group III, but there was no difference be-
tween group I and group II. At day 7, the number of total group III. Through all periods of this experiment, the

Fig. 3. Light microscopic findings and expression of TGF-IIR, -SMA, and fibronectin-EDA at day 7. Immunostaining micrograph shows TGF-IIR
expression in normal rat kidney (A 400) and anti-Thy-1 nephritis rat kidney at day 7 (B 400). TGF-IIR was expressed in glomerulus, especially
in glomerular epithelial cells, and faintly in tubular epithelial cells in normal rat kidney (A). TGF-IIR expression was increased in both glomerulus
and tubules in Thy-1 nephritis at day 7 (B). Light microscopic appearance at day 7 (PAS stain 400 C, D, E: C, group I; D, group II; E, group
III). The mesangial area was expanded in group II (D) compared with group III (E). Injection of anti-TGF-IIR antibody (group I) suppressed
mesangial expansion (C) compared to group II (D). Immunostaining micrograph shows -SMA expression in glomerulus (F, G, H, 200),
fibronectin-EDA expression in glomerulus (I, J, K, 200) and in interstitium (L, M, N, 200) (group I is in panels F, I, L; group II, panels G, J,
M; group III, panels H, K, N). The expression of -SMA and fibronectin-EDA was not detected or weakly positive in group III (H, K, N) and
increased in group II (G, J, M). The expression of both proteins in group I (F, I, L) was significantly reduced when compared to group II.
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Fig. 5. Quantitative measurement of -smooth muscle actin (-SMA),
fibronectin-EDA and type I collagen in glomeruli and in interstitium.
Symbols are: ( ) group 1; ( ) group II; ( ) group III. (A) In glomeruli,
the positively stained areas for -SMA, fibronectin-EDA and type I colla-
gen were significantly increased in group II compared with group III
(fibronectin-EDA, #P 
 0.0001; type I collagen, ##P 
 0.0001; -SMA,
###P 
 0.0001). The positively stained area for these proteins was
significantly reduced in group I when compared to group II (fibronectin-
EDA, *P 
 0.0001; type I collagen, **P 
 0.0001; -SMA, ***P 

0.005, respectively). (B) The ratio of positively stained area for fibro-
nectin-EDA or type I collagen in a randomly selected tubulointerstitial
compartment (0.1 mm2) was significantly increased in group II compared
with group III (fibronectin-EDA, #P 
 0.0001; type I collagen, ##P 
 Fig. 6. Total glomerular cells and macrophages. Symbols are: ( )
0.05). The positively stained area for both proteins was significantly group 1; ( ) group II; ( ) group III. (A) At day 1 and day 3, the
reduced in group I when compared with group II (fibronectin-EDA, number of total glomerular cells in group I and II was significantly
*P 
 0.0001; type I collagen, **P 
 0.05, respectively). decreased compared with group III, but there was no difference between
group I and group II. At day 7, the number of total glomerular cells
in groups I and II was significantly increased compared with group III,
and that of group I was reduced compared with group II. The difference
between each of the two groups was statistically significant (*P
 0.0001
number of glomerular macrophages in groups I and II vs. group III; #P 
 0.0001 vs. group III; **P 
 0.0001 vs. group III;
##P 
 0.0001 vs. group III; ***P 
 0.01 vs. group II, P 
 0.0001 vs.was significantly increased compared with group III. In-
group III; ###P 
0.0001 vs. group III, respectively). (B) The numberfiltration of glomerular macrophages in group I was not
of glomerular macrophages in groups I and II was significantly increased
different at day 1 and day 3, but significantly inhibited compared to group III through all periods. There was no difference
between group I and group II at day 1 and day 3, but that of group Iat day 7 when compared with group II (Fig. 6B).
was reduced compared to group II at day 7 (*P 
 0.0001 vs. group III;
#P 
 0.0001 vs. group III; **P 
 0.0001 vs. group III; ##P 
 0.0001
vs. group III; ***P 
 0.005 vs. group II, P 
 0.0001 group III; ###P 

DISCUSSION 0.0001 vs. group III).
Several targeting points and methods have been re-
ported to prevent renal fibrosis through inhibition of
TGF- signaling pathway: (1) direct inhibition of TGF-
synthesis by application of antisense oligonucleotides [5];
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(2) TGF- inhibition by neutralizing antibody [4] or by on TGF-IIR blockade. In addition, the number of total
glomerular cells was slightly but significantly decreasednatural inhibitor of TGF-, decorin [6, 7]; (3) soluble
chimeric TGF- receptor [8], which competitively block when compared to group II. In general, several investiga-
tors reported that, in vitro, TGF- was an inhibitor ofthe binding of TGF- to its receptors; and (4) TGF-
intracellular signaling pathway inhibition by specific in- mitogenesis in glomerular cells [26, 27]. In an in vivo
situation, however, the effects of TGF- on glomerularhibitor for Rho-associated coiled-coil forming protein ki-
nase (ROCK) (abstract; Nagatoya et al, J Am Soc Nephrol cell proliferation are still controversial. Introduction of
TGF- gene into the rat glomerular mesangium was re-11:534A, 2000), which is the downstream of Rho, an
another TGF- signaling pathway [17, 18]. Also, angio- ported to induce not only ECM deposition, but also
modest mitogenesis of resident cells [28]. These findingstensin-converting enzyme (ACE) inhibitors and angio-
tensin II type I receptor (AT1) antagonists, which have might explain that blocking for TGF-IIR reduced the
total number of glomerular cells at day 7. Further studiesalready been clinically used, are known to be renoprotec-
tive agents by reducing TGF- expression as well as are needed to determine the in vivo effects of TGF-
on the glomerular cell proliferation.decrease of intraglomerular capillary pressure [19–21].
Dietary protein restriction reduces TGF- expression as Transforming growth factor- was reported to have
an anti-inflammatory function [9, 29]. In our study, thewell [22]. However, there have been no reports demon-
strating that blocking of TGF- receptor function pre- number of macrophages in early phase was not different
between group I and group II. Therefore, we thought thatvents renal fibrosis. Our studies showed for the first time
that direct inhibition of TGF-IIR is effective to prevent JMAb-45 did not influence on macrophage infiltration
at early time point of this experiment. However, macro-ECM deposition using rat anti-Thy-1 nephritis.
The present work tested the effects of a fully human phage infiltration was significantly inhibited at day 7. While
the difference was small (group I, 3.4	 0.3 macrophages/monoclonal antibody against TGF-IIR in a rat anti-
Thy-1 nephritis. First, we studied expression of TGF-IIR glomerulus; group II, 4.8	1.2 macrophages/glomerulus),
we cannot ignore the possibility that JMAb-45 mightin the kidneys from normal rats and anti-Thy-1 nephritis
rats at day 7. In the normal condition, TGF-IIR is influence macrophage infiltration. More investigations
are required to define this question.strongly expressed in glomerular visceral epithelial cells
and weakly in the apical site of tubular epithelial cells. Urinary protein excretion was significantly decreased
in group I compared with group II. In other studies theRecently, TGF- 2 and 3 have been shown to be ex-
pressed in glomerular visceral epithelial cells as well as decrease of urinary protein excretion was indicated in
anti-Thy-1 nephritis animals treated with decorin admin-TGF-IIR [16, 23]. Interaction of TGF- and TGF-IIR
may contribute to maintain the structure and function istration or with decorin gene therapy [6, 7], which atten-
uated TGF-. Heparan sulfate proteoglycans (HSPG) areof glomerular capillary wall in normal rat glomerulus.
Administration of 1-22-3 monoclonal antibody to rats components of glomerular basement membrane (GBM),
and HSPG alterations may contribute to the GBM’s per-leads to proliferative glomerulonephritis [15], which is
characterized by complement-dependent injury of mesan- meability. One of the mechanisms leading to a reduced
HSPG function is depolymerization by oxygen or nitro-gial cells, followed by mesangial proliferation [15, 24, 25].
Then transient ECM deposition is observed. Previous gen radicals [30]. TGF- was reported to increase GBM
permeability via reactive oxygen species (ROS) produc-studies demonstrated that TGF- was a crucial factor for
accumulation of ECM in this model at day 7 [4–8, 16]. tion of glomerular resident cells [31]. It is possible that
ROS production might be reduced by anti-TGF-IIR anti-TGF- was increased in the mesangial proliferative le-
sions and peaked at day 7 [16], whereas expression of body treatment. Serum creatinine also was decreased in
group I rats. Improvement of glomerular morphologicalTGF-IIR has not been studied yet. As expected, TGF-
IIR was dramatically up-regulated in the mesangial pro- and functional changes by JMAb-45 might contribute to
the improved creatinine level. In addition, tubulointersti-liferative lesions, tubular epithelial cells, and interstitial
cells of the kidneys from anti-Thy-1 nephritis obtained tial damage ameliorated by anti-TGF-IIR antibody injec-
tion might have influenced on serum creatinine level [32].at day 7. In this experiment, rats were divided into three
groups to explore the effects of the fully human anti- Transforming growth factor- is well known as a major
promoter of myofibroblast differentiation. In mesangialTGF-IIR monoclonal antibody (JMAb-45). In group I,
TGF-IIR antibody apparently reduced the deposition cells, TGF- induces -SMA expression (abstract; Imai
et al, J Am Soc Nephrol 5:782, 1994) [33] and enhancesof fibronectin-EDA and type I collagen. Physiological
and histological findings at day 1 and day 3 were not synthesis of ECM including fibronectin-EDA [34]. Anti-
EDA monoclonal antibody specifically blocks TGF-–different between group I and group II. Therefore, we
thought that the injection of JMAb-45 did not influence induced expression of -SMA but not that of plasmino-
gen activator inhibitor-1 [35]. In anti-Thy-1 nephritis aton the early phase of this model, and believed that the
difference in ECM deposition at day 7 was dependent day 7, JMAb-45 reduced -SMA expression as well as
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the expression of fibronectin and collagen and their incorporationfibronectin-EDA. Taken together, suppression of fibro-
into the extracellular matrix. J Biol Chem 261:4337–4345, 1986
nectin-EDA deposition by TGF-IIR antibody via inhi- 3. Baricos WH, Cortez SL, Deboisblanc M, Xin S: Transforming
bition of TGF- signaling pathway might lead to the growth factor- is a potent inhibitor of extracellular matrix degra-
dation by cultured human mesangial cells. J Am Soc Nephroldecrease in myofibroblast differentiation of mesangial
10:790–795, 1999
cells. 4. Border WA, Okuda S, Languino LR, et al: Suppression of experi-
The Xenomice used in this experiment are murine mental glomerulonephritis by antiserum against transforming
growth factor 1. Nature 346:371–374, 1990immunoglobulin (Ig) knockout and human Ig transgenic
5. Akagi Y, Isaka Y, Arai M, et al: Inhibition of TGF-1 expressionmice [12, 13] capable of producing human antibodies by antisense oligonucleotides suppressed extracellular matrix accu-
against human antigens. The usefulness of mouse mono- mulation in experimental glomerulonephritis. Kidney Int 50:148–
155, 1996clonal antibodies [36] or mouse/human chimera antibod-
6. Border WA, Noble NA, Yamamoto T, et al: Natural inhibitor ofies [37] could be restricted in the clinical setting because transforming growth factor- protects against scarring in experi-
of the immune response against mouse antibodies [38] mental kidney disease. Nature 360:361–364, 1992
7. Isaka Y, Brees DK, Ikegaya K, et al: Gene therapy by skeletalor by the difficulty in obtaining high affinity chimera
muscle expression of decorin prevents fibrotic disease in rat kidney.antibody. Antibodies from Xenomice are able to over- Nat Med 2:418–423, 1996
come these problems. JMAb-45 is a fully human mono- 8. Isaka Y, Akagi Y, Ando Y, et al: Gene therapy by transforming
growth factor- receptor-IgG Fc chimera suppressed extracellularclonal antibody and is expected for the therapy of human
matrix accumulation in experimental glomerulonephritis. Kidneydiseases in the future, though more studies are required Int 55:465–475, 1999
before clinical use. 9. Blobe GC, Schiemann WP, Lodish HF: Role of transforming
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